Status:
COMPLETED
Effect of Abdominal Obesity on Lipoprotein Metabolism
Lead Sponsor:
The University of Western Australia
Conditions:
Obesity
Dyslipidemia
Eligibility:
MALE
18-65 years
Phase:
PHASE3
Brief Summary
Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. Weight reduction is suggested to be a preferred...
Detailed Description
We examined the mechanism of the effect of weight loss through dieting on LDL and HDL metabolism in abdominally obese men. LDL apoB-100 and HDL apoA-I kinetics were studied using a primed-constant inf...
Eligibility Criteria
Inclusion
- Obesity was defined as a body mass index (BMI) \>28kg/m2 and visceral visceral obesity (waist to hip ratio\> 1.0 or waist circumference \>100 cm)
Exclusion
- Diabetes mellitus,
- Proteinuria,
- Hypothyroidism,
- Abnormal liver enzymes,
- Major systemic illness,
- A history of alcohol abuse,
- A family history of hyperlipidemia or premature coronary artery disease or were taking medication known to affect lipid metabolism.
Key Trial Info
Start Date :
January 1 1995
Trial Type :
INTERVENTIONAL
End Date :
December 1 1998
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00438061
Start Date
January 1 1995
End Date
December 1 1998
Last Update
February 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Perth Hospital
Perth, Western Australia, Australia, 6000